Korean J Adult Nurs.  2016 Jun;28(3):314-322. 10.7475/kjan.2016.28.3.314.

Quality of Life in Patients with Multiple Myeloma

  • 1Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul, Korea.
  • 2College of Nursing, The Catholic University of Korea, Seoul, Korea. ysyoo@catholic.ac.kr


The purpose of this study was to identify the quality of life reported by patients with multiple myeloma and secondly to identify the factors that impact the quality of life (QoL).
189 patients with multiple myeloma completed survey questionnaires. Quality of life was evaluated using European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core (EORTC QLQ-C) 30 and Multiple Myeloma (MY) 20. The data were analyzed using the t-test, ANOVA, Kruskal-Wallis test, Duncan test and the Mann-Whitney test.
The mean score for each subscale of EORTC QLQ-C30 was 53.35 for global health status, 73.37 for functional scale, and 31.29 for symptom scale. The mean score for each subscale of EORTC QLQ-MY20 was 60.49 for future perspective, 59.78 for body image, 20.25 for disease symptom and 24.99 for side effect of treatment. Quality of life was reported to be significantly lower among females, unemployed, dependence on a sibling for financial support for treatment, a diagnosis of anemia, having treatment, high score on Eastern Coorperative Oncology Group and high grade peripheral neuropathy.
The results of the survey can identify characteristics impacting the QoL of patients with multiple myeloma. Developing appropriate educational strategies and nursing interventions would enhance their QoL.

MeSH Terms

Body Image
Financial Support
Global Health
Multiple Myeloma*
Peripheral Nervous System Diseases
Quality of Life*

Cited by  1 articles

Factors Affecting Cognitive Function in Patients with Stomach Cancer
Yeoung Ji Yu, Seung Hee Ahn, Yong Ae Cho, Eunjung Ryu, Eun-Ju Kim
Asian Oncol Nurs. 2018;18(4):241-246.    doi: 10.5388/aon.2018.18.4.241.


1.Kumar S. Treatment of newly diagnosed multiple myeloma: advances in current therapy. Medical Oncology. 2010. 27(Suppl 1):S14–24. http://dx.doi.org/10.1007/s12032-009-9370-1.
2.Bilotti E., Faiman BM., Richards TA., Tariman JD., Miceli TS., Rome SI. Survivorship care guidelines for patients living with multiple myeloma: consensus statements of the international myeloma foundation nurse leadership board. Clinical Journal of Oncology Nursing. 2011. 15(4):5–8. http://dx.doi.org/10.1188/11.s1.cjon.5-8.
3.Smith D., Yong K. Multiple myeloma. British Medical Journal. 2013. 346:3863. http://dx.doi.org/10.1136/bmj.f3863.
4.Cocks K., Cohen D., Wisloff F., Sezer O., Lee S., Hippe E, et al. An international field study of the reliability and validity of a disease-specific questionnaire module (the QLQ-MY20) in assessing the quality of life of patients with multiple myeloma. European Journal of Cancer. 2007. 43(11):1670–8. http://dx.doi.org/10.1016/j.ejca.2007.04.022.
5.Palumbo A., Attal M., Roussel M. Shifts in the therapeutic paradigm for patients newly diagnosed with multiple myeloma: maintenance therapy and overall survival. Clinical Cancer Research. 2011. 17(6):1253–63. http://dx.doi.org/10.1158/1078-0432.ccr-10-1925.
6.Comert M., Gunes AE., Sahin F., Saydam G. Quality of life and supportive care in multiple myeloma. Turkish Journal of Haematology. 2013. 30(3):234–46. http://dx.doi.org/10.4274/Tjh.2012.0192.
7.Jordan K., Proskorovsky I., Lewis P., Ishak J., Payne K., Lordan N, et al. Effect of general symptom level, specific adverse events, treatment patterns, and patient characteristics on health-related quality of life in patients with multiple myeloma: results of a European multicenter cohort study. Supportive Care in Cancer. 2014. 22(2):417–26. http://dx.doi.org/10.1007/s00520-013-1991-4.
8.Osborne TR., Ramsenthaler C., Siegert RJ., Edmonds PM., Schey SA., Higginson IJ. What issues matter most to people with multiple myeloma and how well are we measuring them? A systematic review of quality of life tools. European Journal of Haematology. 2012. 89(6):437–57. http://dx.doi.org/10.1111/ejh.12012.
9.Sherman AC., Simonton S., Latif U., Plante TG., Anaissie EJ. Changes in quality-of-life and psychosocial adjustment among multiple myeloma patients treated with high-dose melphalan and autologous stem cell transplantation. Biology of Blood and Marrow Transplantation. 2009. 15(1):12–20. http://dx.doi.org/10.1016/j.bbmt.2008.09.023.
10.Khalafallah A., McDonnell K., Dawar HU., Robertson I., Woods D. Quality of life assessment in multiple myeloma patients undergoing dose-reduced tandem autologous stem cell transplantation. Mediterranean Journal of Hematology and Infectious Disease. 2011. 3(1):e2011057. http://dx.doi.org/10.4084/mjhid.2011.057.
11.Sonneveld P., Verelst SG., Lewis P., Gray-Schopfer V., Hutchings A., Nixon A, et al. Review of health-related quality of life data in multiple myeloma patients treated with novel agents. Leukemia. 2013. 27(10):1959–69. http://dx.doi.org/10.1038/leu.2013.185.
12.Corso A., Mangiacavalli S., Cocito F., Pascutto C., Ferretti VV., Pompa A, et al. Long term evaluation of the impact of autologous peripheral blood stem cell transplantation in multiple myeloma: a cost-effectiveness analysis. The Public Library of Science One. 2013. 8(9):e75047. http://dx.doi.org/10.1371/journal.pone.0075047.
13.Stead ML., Brown JM., Velikova G., Kaasa S., Wisloff F., Child JA, et al. Development of an EORTC questionnaire module to be used in health-related quality-of-life assessment for patients with multiple myeloma. European Organization for Research and Treatment of Cancer Study Group on Quality of Life. British Journal of Haematology. 1999. 104(3):605–11.
14.Kontodimopoulos N., Samartzis A., Papadopoulos AA., Niakas D. Reliability and validity of the Greek QLQ-C30 and QLQ-MY20 for measuring quality of life in patients with multiple myeloma. The Scientific World Journal. 2012. 2012:842–67. http://dx.doi.org/10.1100/2012/842867.
15.Kim HS., Yi MS. Factors influencing quality of life in multiple myeloma. Asian Oncology Nursing. 2015. 15(1):9–17.
16.Oken MM., Creech RH., Tormey DC., Horton J., Davis TE., Mc-fadden ET, et al. Toxicity and response criteria of the eastern cooperative oncology group. American Journal of Clinical Oncology. 1982. 5(6):649–55.
17.Miller AB., Hoogstraten B., Staquet M., Winkler A. Reporting results of cancer treatment. Cancer. 1981. 47(1):207–14.
18.Jung JY., So HS., Hong JE., Chea MJ., Han KH. Related factors to quality of life among hospitalized cancer patients undergoing chemotherapy. Asian Oncology Nursing. 2012. 12(1):84–91.
19.Jung KH., Kim KH., Gwak YH. Quality of life in colorectal cancer patients according to the severity of symptom clusters classification. Asian Oncology Nursing. 2014. 14(2):74–83.
20.Kim JH., Choi KS., Kim T., Hong YS. Quality of life in colorectal cancer patients with chemotherapy-induced peripheral neuropathy. Asian Oncology Nursing. 2011. 11(3):254–62.
21.Yang JY., Lee MS. Factors influencing quality of life in thyroid cancer patients with thyroidectomy. Asian Oncology Nursing. 2015. 15(2):59–66.
22.Kim KD., Jang HJ. Effect of pain, sleep, disturbance and fatigue on the quality of life in patients with pancreatic cancer undergoing chemotherapy. Asian Oncology Nursing. 2012. 12(2):117–24.
23.Can G., Demir M., Erol O., Aydiner A. A comparison of men and women's experiences of chemotherapy-induced alopecia. European Journal of Oncology Nursing. 2013. 17(3):255–60. http://dx.doi.org/10.1016/j.ejon.2012.06.003.
24.Goodwin JA., Coleman EA., Sullivan E., Easley R., McNatt PK., Chowdhury N, et al. Personal financial effects of multiple myeloma and its treatment. Cancer Nursing. 2013. 36(4):301–8. http://dx.doi.org/10.1097/NCC.0b013e3182693522.
25.Kirchhoff AC., Leisenring W., Syrjala KL. Prospective predictors of return to work in the 5 years after hematopoietic stem cell transplantation. Journal of Cancer Survivorship: Research and Practice. 2010. 4(1):33–44. http://dx.doi.org/10.1007/s11764-009-0105-2.
26.Song BE., Kang HR., Kim KS. Quality of life in patients with hematopoietic stem cell transplantation. Asian Oncology Nursing. 2008. 8(1):40–9.
27.Jo OH., Park LH., Yang NY., Hwang KH. Mood state, interaction anxiety and quality of life of cancer patients with chemotherapy-induced alopecia. Asian Oncology Nursing. 2013. 13(4):193–200.
28.Faiman B. Clinical updates and nursing considerations for patients with multiple myeloma. Clinical Journal of Oncology Nursing. 2007. 11(6):831–40. http://dx.doi.org/10.1188/07.cjon.831-840.
29.Kim HY., Kang JH., Song JE., Yoon HJ. Chemotherapy-induced peripheral neuropathy and quality of life in breast cancer patients. Asian Oncology Nursing. 2013. 13(4):222–30.
30.Kurtin S., Faiman B. The changing landscape of multiple myeloma: implications for oncology nurses. Clinical Journal of Oncology Nursing. 2013. 17(Suppl):7–11. http://dx.doi.org/10.1188/13.cjon.s2.7-11.
Full Text Links
  • KJAN
export Copy
  • Twitter
  • Facebook
Similar articles
Copyright © 2023 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr